Key Takeaways Strategic brands and pipeline momentum, especially in oncology and rare diseases, are driving revenue growth, supported by global demand in expanding and aging populations. Cost optimization and accelerated R&D productivity are enhancing profitability, with partnerships and emerging market uptake offering further upside to future earnings.Read more
Key Takeaways Loss of exclusivity for major drugs and persistent R&D challenges threaten future revenue stability and hinder the replacement of expiring blockbusters. Pricing pressures, regulatory risks, and supply chain complexities increase margin volatility and operational uncertainty across key global markets.Read more
Key Takeaways Outperformance by key brands and rapid global market expansion suggest potential upside to revenue and long-term growth as adoption and market penetration accelerate. Faster-than-expected cost reductions and advanced R&D strategies are increasing profitability and positioning Astellas for leadership in innovative, high-value therapeutics.Read more
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD); EVRENZO, a treatment for anemia associated with chronic kidney disease (CKD); Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressants. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. It offer its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
